Unity Btech Stock Price, News & Analysis

UNITY Biotechnology (Nasdaq: UBX) announced an Investor/Analyst Day on October 12, 2022, at 5:00 a.m. PT/8:00 a.m. ET. The event will focus on age-related eye diseases and the potential treatment solution offered by its lead program, UBX1325.

Key discussions will include insights from Robert B. Bhisitkul, M.D., Ph.D., on the mechanism of action of UBX1325, along with recent clinical data from the BEHOLD study in Diabetic Macular Edema and the ENVISION study in wet Age-related Macular Degeneration.

UNITY Biotechnology has successfully completed patient enrollment for the ENVISION study, a Phase 2 clinical trial of its investigational compound UBX1325, aimed at treating wet age-related macular degeneration (AMD). A total of 51 patients were enrolled, exceeding targets by approximately 10%. The trial will compare UBX1325 against aflibercept over 24 weeks. Key data readouts are anticipated in Q1 and Q2 2023, with the company expressing optimism about UBX1325's potential to impact retinal disease treatments significantly.

UNITY Biotechnology, Inc. (Nasdaq: UBX) announced participation in key investor conferences this September, aimed at discussing their innovative therapeutics targeting aging diseases. The company will hold one-on-one meetings at the Citi 17th Annual BioPharma Conference from September 6-8 in Boston, and present a corporate update at the H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 4 PM ET, available via webcast. UNITY focuses on treatments that eliminate senescent cells to benefit age-related ophthalmologic and neurologic conditions.

UNITY Biotechnology (Nasdaq: UBX) has priced an upsized public offering of 64,285,714 shares and warrants at $0.70 each, projected to raise approximately $45 million before expenses. The offering, closing on August 22, 2022, aims to finance ongoing clinical studies for UBX1325 and support general corporate needs. The warrants carry an exercise price of $0.85 and are valid for five years. This offering, managed by SVB Securities, Cantor, and Mizuho, follows a previously effective registration with the SEC.

UNITY Biotechnology announced a proposed underwritten public offering of $25 million of its common stock. The offering includes a 30-day option for underwriters to purchase an additional 15% of shares. Proceeds will be used for ongoing clinical development of UBX1325, which includes BEHOLD and ENVISION studies, as well as general corporate purposes. The offering is subject to market conditions and other factors.

UNITY Biotechnology announced positive results from the Phase 2 BEHOLD study of UBX1325 for Diabetic Macular Edema, showing significant improvements in BCVA and CST with a favorable safety profile at 12 and 18 weeks. The company reported a cash position of $64.5 million as of June 30, 2022. Upcoming milestones include 24-week data from BEHOLD and 16-week data from the ENVISION study by year-end. Additionally, the Tie2/VEGF bispecific program has been advanced as a candidate, strengthening its pipeline.

UNITY Biotechnology reported significant results from the Phase 2 BEHOLD study of UBX1325 for diabetic macular edema (DME). After 18 weeks, subjects treated with a single injection of UBX1325 showed an improvement of +6.1 ETDRS letters in Best Corrected Visual Acuity (BCVA) compared to sham treatment (p = 0.0368). Additionally, UBX1325 stabilized retinal structure, evidenced by central subfield thickness (CST), while sham-treated patients experienced worsening conditions. The treatment demonstrated a favorable safety profile without serious complications, indicating the potential for UBX1325 to offer a long-lasting, disease-modifying alternative to current therapies.

UNITY Biotechnology (Nasdaq: UBX) will host an investor call on August 12, 2022, at 5:00 a.m. PT/8:00 a.m. ET, featuring retinal expert Robert Bhisitkul, M.D., Ph.D. The discussion will center around its lead program, UBX1325, aimed at developing therapies targeting age-related diseases. The call will be accessible via their website, with a replay available shortly after. UNITY is focused on innovative therapeutics to combat aging diseases by eliminating senescent cells, with implications for ophthalmologic and neurologic conditions.

UNITY Biotechnology (NASDAQ: UBX) announced the presentation of 24-week clinical data from its Phase 1 study of UBX1325 at the ASRS 40th Annual Scientific Meeting, scheduled for July 14, 2022. UBX1325 is being developed for treating diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The investigational therapy has shown a favorable safety profile and improvements in visual acuity. The company aims to offer transformative outcomes for patients suffering from age-related ocular diseases.